Eli Lilly has responded to President Donald Trump’s administration plan to lower US drug costs by announcing plans to raise prices in European countries. The company says it will align its prices with those paid in other developed markets, including the UK.
Lilly is working with the UK government to increase the price of its diabetes medicine Mounjaro while maintaining access for patients. However, the company did not commit to reducing US prices and instead suggested that governments and health systems need to increase their payments in other markets for prices to be lowered in the US.
The “most favored nation” policy aims to link US drug prices to those paid in other high-income countries. Eli Lilly objects to pharmaceutical levies, arguing they would raise costs, limit patient access, and undermine American leadership.
In its statement, Lilly called on the administration and Congress to prioritize strategic incentives that strengthen US manufacturing and supply-chain resilience without sacrificing access, affordability, innovation, or American leadership. The company expects to make necessary pricing adjustments by September 1.
Source: https://www.biopharmadive.com/news/lilly-drug-prices-europe-most-favored-nation-uk-mounjaro/757704